Janssen CarePath provides injection support resources that may assist you and your patients.
TREMFYA® Injection Training Support Program
The TREMFYA® Injection Training Support Program provides patients with additional training support to continue their TREMFYA® treatment with confidence.
How the Program works:
- The self-injection training is conducted live by a Registered Nurse, either in-person or over the phone.*
- Your patient can only enroll once you, their healthcare provider, and your patient have confirmed that initial self-injection training has been completed in your office.
- This program is intended as patient education to reinforce proper injection technique.
To have your patients enroll in the TREMFYA® Injection Training Support Program, they must first fill out a program enrollment form, which you can provide after they have met the program eligibility requirements.
The TREMFYA® Injection Training Support Program is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.
*In-person live training may not be available in all areas.
A Nurse is Just a Phone Call Away
Even after you’ve trained your patients to give themselves an injection of TREMFYA®, they may still have questions. Janssen Nurse Support* can help answer their questions about giving themselves an injection at home, preparing their injection site prior to self-injecting, and properly disposing of their used syringe.
Connect your patients with Janssen Nurse Support at 877-CarePath (877-227-3728), available Monday-Friday, 9:00 AM to 8:00 PM ET. At all other times, a nurse will typically return their call in 15 minutes.
*Nurse Support is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.
TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.
The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.